InnoCare Pharma
(1)(2)(3)(4)
(5)(6)(7)
(8)(9)
(10)
88AGM-1AGM-8(www.hkexnews.hk)( www.innocarepharma.com)
17M
– i –
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
3.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
5.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
9.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
11.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
13.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
15.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
16. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
17. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
— . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I-1
— . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . II-1
— . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . III-1
— . . . . . . . . . . . . . . . . . . IV-1
— . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V-1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . AGM-1
– 1 –
AGM-1AGM-8
9969688428
– 2 –
7%
93%7%
0.000002
III-2
– 3 –
– 4 –
a.b.
c.
0.000002
0.000002
– 5 –
1.01
%
– 6 –
InnoCare Pharma
Ogier Global (Cayman) Limited89 Nexus Way, Camana BayGrand Cayman, KY1-9009Cayman Islands
(1)(2)(3)(4)
(5)(6)(7)
(8)(9)
(10)
– 7 –
1.
AGM-1AGM-8
(1)(2)(3)
(4)(5)(6)
(7)(8)
(9)
2.
(http://www.sse.com.cn)(http://www.hkexnews.hk)(www.innocarepharma.com)
(http://www.hkexnews.hk)(http://www.sse.com.cn)(www.innocarepharma.com)
3.
– 8 –
4.
5.
20%
1,762,582,452
352,516,4907
– 9 –
520%
10%
1,497,934,235264,648,2177
149,793,42326,464,821
6.
114.(a)
– 10 –
7.
(a)
(b) 3.13
(c)
– 11 –
3.13
8.
9.
– 12 –
10.
11.
(i)(ii)
A1
– 13 –
12.
183171712-1716
13.
AGM-1AGM-8
(i)(ii)(iii)
14.
( www.hkexnews.hk)( www.innocarepharma.com)
– 14 –
15.
16.
– 15 –
17.
(1)(2)
(3)(4)
(5)(6)(7)
(8)(9)
– I-1 –
2023
2023
—
2023
2023
2023NMPAMZLMZLBTKtafasitamab
13I/II/III
2.0
2023
202315
– I-2 –
12023.01.19222023.02.15132023.03.271742023.04.20152023.04.261462023.05.09272023.06.02282023.07.11292023.07.142102023.08.116112023.08.293122023.09.081132023.10.114142023.11.132152023.12.152
1 A
277,881.562023
20222023
– I-3 –
—
— A
—
– I-4 –
A
A
e
20232
– I-5 –
2023
20237
20236
20233
– I-6 –
2024
2024
—
2024328
– II-1 –
13.51(2)
Ph.D.56
(PrincetonUniversity)
(The National Science Fund for Distinguished
Young Scholars)(The Irving Sigal YoungInvestigator Award)(The
Raymond & Beverly Sackler International Prize)
(The Gregori Aminoff Prize,
Royal Swedish Academy of Sciences)
– II-2 –
(The National Innovation Award)
Structures of the Human Spliceosomes Before and After Release of the Ligated
ExonStructures of the Catalytically Activated Yeast Spliceosome Reveal the Mechanism of
Branching Recognition of the Amyloid Precursor Protein by Human–Secretase Structural Basis of Notch Recognition by Human–Secretase Structure of a Human Catalytic Step I SpliceosomeStructures of the Fully Assembled Saccharomyces Cerevisiae Spliceosome Before
Activation Structure of the Human PKD1/PKD2 Complex Structures of the Human Pre-Catalytic Spliceosome and its Precursor Spliceosome
(Johns Hopkins University)
XV116,839,593
– II-3 –
5020
XV
1875
Arthur Andersen
CICPA
– II-4 –
30,000
XV
ArriVent Biopharma, Inc.ArriVent Biopharma, Inc.
Vivo Capital LLCVivo Capital LLCVivo CapitalVivo PANDA FundVivoInnovation Fund II
Pre-doctoral Fellowship
30,000
XV
– II-5 –
3.13
(i)(ii)(iii)
13.51(2)(h)(v)
– III-1 –
10%10%
(i)(ii)12(iii)(iv)
(v)
1,497,934,235264,648,217
10%
149,793,423
– III-2 –
26,464,82110%
– III-3 –
(i)
(ii)
(iii)
– III-4 –
HHLR Advisors, Ltd.208,671,22211.84%HHLRAdvisors, Ltd.13.15%
1,650,0005.134.548,138,430
548,0006.005.603,162,780180,0006.666.461,191,470
2,378,00012,492,680
– III-5 –
10.907.90
9.607.08
8.386.45
8.387.05
8.376.56
6.845.67
6.385.31
7.495.93
6.975.88
6.955.28
5.554.50
5.514.61
5.064.03
– IV-1 –
64.(a)
64.(a)
97.(b)
97.(b)
– IV-2 –
185.(b)(c)
185.(b)(c)
– IV-3 –
185.(c)185.(c)
– IV-4 –
190.(b)
190.(b)
191.(a)191.(a)[]
– IV-5 –
191.(b)
(b)
191.(b)
[]
(b)
– IV-6 –
191.(c)
(b)
191.(c)
[]
(b)
– IV-7 –
192.192.
(a)
(b)
(c)
(d)(e)
– IV-8 –
193.193.
195.195.
– V-1 –
20187
93,000
86,490
130,000
2024328
– V-2 –
2018814
91440101MA5C44KG8LCUI Jisong100,000
93%7%
– V-3 –
20231231208,551.13161,182.99
47,368.1420238,623.37–20,097.07–15,484.74 20231231
– V-4 –
293,740
41.09%
18.19%12
170,000
17.14%
13.10%
– AGM-1 –
InnoCare Pharma
1.
2.3.4.5.
(i) (iii)
(v)
– AGM-2 –
(ii) (i)
(iii) (i)
(1) (v)(2)
(3)
(4)
20%
– AGM-3 –
(i)
(v)(ii)
(iv)
(v)
(a) (1)
(2)
(i)(ii)
(iii)
(b)
(1)(2)
(3)
– AGM-4 –
(c)
6.
(i) (ii)(iv)
(ii) (i)
10%
(iii) (i)
10%
– AGM-5 –
(iv) (i)(ii)(iii)(i)(ii)(iii)
(v)
(a)(b)
(c)
(d) 12(e)7.
– AGM-6 –
10%10%8.9.10.11.12.13.
14.15.
16.
A
– AGM-7 –
(i) 567(ii)(iii)
(iv)
18317M
(v)
183171712-1716(vi) 8
(vii) 5
– AGM-8 –
(viii) 6
(ix)(x)